<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570984</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00019640</org_study_id>
    <nct_id>NCT02570984</nct_id>
  </id_info>
  <brief_title>Preventing Asthma in High Risk Kids</brief_title>
  <acronym>PARK</acronym>
  <official_title>Controlling and Preventing Asthma Progression and Severity in Kids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children’s Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a randomized, double-blind, placebo controlled trial designed to test whether
      two years treatment of preschool children aged 2-3 years of age at high risk for asthma with
      omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as
      reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2
      year observation period off study drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prevention/ Disease modification of asthma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">November 27, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 27, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>active asthma diagnosis</measure>
    <time_frame>Final 12 months during 2 year observation period off study drug</time_frame>
    <description>questionnaire</description>
  </primary_outcome>
  <primary_outcome>
    <measure>asthma severity</measure>
    <time_frame>Final 12 months during 2 year observation period off study drug</time_frame>
    <description>questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of positive new allergic sensitization</measure>
    <time_frame>Final 12 months during 2 year observation period off study drug</time_frame>
    <description>skin prick test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>decrease in number of wheezing episodes</measure>
    <time_frame>Final 12 months during 2 year observation period off study drug</time_frame>
    <description>questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>omalizumab 0.016 mg/kg/IU total IgE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>looks like active drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>anti-ige injection</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo comparator arm, injection similar to active</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Parent/guardian must be able to understand and provide signed and dated written
             informed consent; he/she must also be able to communicate with study staff.

          2. 24-47 months of age at randomization

          3. 2-4 wheezing episodes in the past year

          4. positive allergy to aeroallergen

          5. first degree relative with history or current diagnosis of asthma or allergy

          6. Parent-reported history of clinical varicella or administration of varicella vaccine

          7. If is participating in a food immunotherapy treatment that is not part of a clinical
             trial, has been on an established maintenance regimen implemented continuously for a
             minimum of 2 months.

        Exclusion Criteria:

          1. &gt;4 episodes of wheezing in the past year

          2. Use of Step 5 or Step 6 therapy (ICS plus LABA ) at the time of enrollment (Visit 0).

          3. Need for systemic corticosteroids or a hospitalization for respiratory symptoms within
             four weeks prior to screening.

          4. Three or more courses of systemic corticosteroids for wheezing illnesses in the last
             year

          5. More than four days of symptoms of wheezing, or tightness in the chest or cough in the
             past two weeks causing at least minimal limitation of activity

          6. More than four days of albuterol treatment (for symptoms) in the past two weeks

          7. More than one night of symptoms of wheezing, or tightness in the chest or cough
             causing sleep disruption in the past two weeks

          8. More than one night of albuterol treatment (for symptoms) in the past two weeks

          9. Prematurity (&lt;34 weeks gestation)

         10. Need for oxygen for more than 5 days in the neonatal period

         11. History of intubation or mechanical ventilation for respiratory illness

         12. Other significant medical conditions, including: major congenital anomalies, cystic
             fibrosis, chronic pulmonary diseases, bronchopulmonary dysplasia, thoracic surgery,
             history of tuberculosis, immunodeficiency (primary or secondary), seizure disorders

         13. Expecting to relocate within 4 years of study initiation to a place which would make
             in-person clinical visits impossible

         14. Deemed unable to adhere to study activities

         15. Prior aeroallergen immunotherapy or use of biologics including anti-IgE

         16. Prior IVIG or systemic immunosuppressant other than corticosteroids

         17. History of hypoxic seizures during a wheezing episode

         18. Total IgE outside of the omalizumab dosing range.

         19. Enrolled in any clinical medication trial within the past 30 days.

         20. With platelet counts &lt; 150 x 109/L at the Screening Visit (V0)

         21. Past or current medical problems or findings from physical examination or laboratory
             testing that are not listed above, which, in the opinion of the investigator, may pose
             additional risks from participation in the study, may interfere with the participant's
             ability to comply with study requirements or may impact the quality or interpretation
             of the data obtained from the study.

         22. History of severe anaphylactic/anaphylactoid reactions from any cause
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Months</minimum_age>
    <maximum_age>47 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wanda Phipatanakul, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wanda Phipatanakul, MD, MS</last_name>
    <phone>857-218-5336</phone>
    <email>wanda.phipatanakul@childrens.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amparito Cunningham, MD, MPH</last_name>
    <phone>857-218-5336</phone>
    <email>asthma@childrens.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Bauer, MD.</last_name>
      <phone>602-933-3666</phone>
      <email>cbauer@phoenixchildrens.com</email>
    </contact>
    <contact_backup>
      <last_name>Heather Shearer, BSN, RN.</last_name>
      <phone>602-933-0865</phone>
      <email>HShearer@phoenixchildrens.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cindy Bauer, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Martinez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bob Geng, MD</last_name>
      <phone>314-608-8693</phone>
      <email>bgeng@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diba Mortazavi</last_name>
      <phone>858-966-1700</phone>
      <phone_ext>3422</phone_ext>
      <email>dmortazavi@ucsd.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bob Geng, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Childrens H Colorado</last_name>
    </contact>
    <contact_backup>
      <last_name>Darci Anderson</last_name>
      <phone>720-777-0577</phone>
      <email>Darci.anderson@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Connecticut Children's Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tregony Simoneau, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Mathis</last_name>
      <phone>202-476-4698</phone>
      <email>ANewcome@childrensnational.org</email>
    </contact>
    <contact_backup>
      <last_name>Taqwua El-Hussein</last_name>
      <email>telhussein@childrensnational.org</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Teach, MD. MPH.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Fitzpatrick, PhD, NP</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Pongracic, MD.</last_name>
      <phone>312-227-6010</phone>
      <email>JPongracic@luriechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Catalano, BS,LPN,CCRP</last_name>
      <phone>(312) 227-6455</phone>
      <email>MCatalano@luriechildrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jacqueline Pongracic, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University/Riley Children's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kirsten Kloepfer, MD</last_name>
      <phone>317-948-7208</phone>
      <email>kloepfer@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lori Shively, RN, CCRC</last_name>
      <phone>317-278-7121</phone>
      <email>lashivel@iu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amparito Cunningham, MD. MPH.</last_name>
      <phone>857-218-5336</phone>
      <email>amparito.cunningham@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Wanda Phipatanakul, MD. MSc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard Bacharier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisha Hartman, BS</last_name>
      <phone>513-636-1882</phone>
      <email>Alisha.Hartmann@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Theresa Guilbert, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital/Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carla Davis, MD</last_name>
      <phone>832-824-1319</phone>
      <email>carlad@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sopar Seributra, RN, CCRP</last_name>
      <phone>832-824-3911</phone>
      <email>pars@bcm.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Jackson, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Wanda Phipatanakul</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

